Hypertension Experts Push For New Trial Of Renal Denervation To Show Efficacy

Since Medtronic’s sham-controlled SYMPLICITY HTN-3 trial of its Symplicity renal denervation device failed to meet its primary efficacy endpoint, manufacturers developing renal denervation systems have been working with researchers and FDA to map the next steps in researching and developing this hypertension therapy.